home
***
CD-ROM
|
disk
|
FTP
|
other
***
search
/
Collection of Education
/
collectionofeducationcarat1997.iso
/
HEALTH
/
MED9602.ZIP
/
M9620077.TXT
< prev
next >
Wrap
Text File
|
1996-02-26
|
2KB
|
40 lines
Document 0077
DOCN M9620077
TI Hepatotoxicity from isoniazid and rifampin in inner-city AIDS patients.
DT 9602
AU Ozick LA; Jacob L; Comer GM; Lee TP; Ben-Zvi J; Donelson SS; Felton CP;
Department of Medicine, Harlem Hospital Center, Columbia; University,
College of Physicians and Surgeons, New York, New; York, USA.
SO Am J Gastroenterol. 1995 Nov;90(11):1978-80. Unique Identifier :
AIDSLINE MED/96048752
AB OBJECTIVE: To determine the incidence of hepatotoxicity due to isoniazid
and rifampin in inner-city patients with active tuberculosis. DESIGN: A
hospital-based review of 70 consecutive in-patients in a 770-bed,
inner-city hospital. The patient population is primarily
African-American and Hispanic. METHODS: Fifty-eight men and 12 women
were followed from 2-12 wk (median 4 wk). Patients had to be treated for
at least 2 wk to be eligible for the study. Patients were excluded if
they had been on any anti-tuberculous or any other hepatotoxic drug
during the 2-month period before their hospitalization.
Aminotransferases, alkaline phosphatase, bilirubin, and albumin were
obtained at least every 2 wk. RESULTS: Hepatocellular toxicity, defined
as AST and/or ALT greater than 200 IU/L, occurred in eight out of 70
(11.4%) patients. The mean age of these patients was 38.9 yr (22-58 yr).
Patients with AIDS were significantly more likely to develop
hepatotoxicity than those with any other risk factor (p < 0.01).
CONCLUSIONS: Baseline aminotransferases followed by monitoring may be
necessary in AIDS patients.
DE Adult Alanine Aminotransferase/BLOOD Alcoholism/EPIDEMIOLOGY
Antitubercular Agents/*ADVERSE EFFECTS/THERAPEUTIC USE Aspartate
Aminotransferase/BLOOD AIDS-Related Opportunistic Infections/*DRUG
THERAPY/EPIDEMIOLOGY/ MICROBIOLOGY Enzyme Tests Female Hepatitis,
Toxic/DIAGNOSIS/*EPIDEMIOLOGY Human Incidence Isoniazid/*ADVERSE
EFFECTS/THERAPEUTIC USE Liver Function Tests Male New York
City/EPIDEMIOLOGY *Poverty Areas Rifampin/*ADVERSE EFFECTS/THERAPEUTIC
USE Risk Factors Time Factors Tuberculosis, Pulmonary/*DRUG
THERAPY/EPIDEMIOLOGY JOURNAL ARTICLE
SOURCE: National Library of Medicine. NOTICE: This material may be
protected by Copyright Law (Title 17, U.S.Code).